Amit Kumar Acquires 5,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The shares were acquired at an average cost of $3.47 per share, for a total transaction of $17,350.00. Following the completion of the acquisition, the chief executive officer directly owned 657,000 shares of the company’s stock, valued at approximately $2,279,790. This trade represents a 0.77% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.46 per share, with a total value of $17,300.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.04 per share, for a total transaction of $15,200.00.
• On Friday, June 12th, Amit Kumar acquired 21,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $3.41 on Wednesday. The stock has a fifty day moving average price of $3.00 and a 200-day moving average price of $2.93. The company has a market cap of $116.01 million, a price-to-earnings ratio of -11.00 and a beta of 0.55. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. Research analysts predict that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on ANIX. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Zacks Research raised shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Anixa Biosciences presently has an average rating of “Moderate Buy” and an average price target of $8.50.

Institutional Trading of Anixa Biosciences

Several large investors have recently bought and sold shares of ANIX. NewEdge Advisors LLC acquired a new position in Anixa Biosciences during the second quarter worth about $33,000. Cetera Investment Advisers acquired a new stake in shares of Anixa Biosciences in the 4th quarter valued at approximately $35,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. bought a new stake in shares of Anixa Biosciences during the 2nd quarter valued at approximately $37,000. Finally, Millennium Management LLC acquired a new position in Anixa Biosciences during the 4th quarter worth approximately $38,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.